11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 30.06.2026 Expectation: 3300 pips
Buying USDCAD up to 1.41500
Today at 11:21 AM 11
Period: 17.04.2026 Expectation: 700 pips
AUDCAD is at risk of correction amid fragile Middle East truce
Today at 10:34 AM 11
Gold buy
Period: 30.04.2026 Expectation: 800 pips
Invest in gold once $4,800 gives way
Today at 09:23 AM 25
Brent sell
Period: 17.04.2026 Expectation: 630 pips
Brent crude sell-off targets $92.5
Today at 08:44 AM 17
Period: 17.04.2026 Expectation: 920 pips
Friday profit-taking puts GBPUSD buyers on sidelines
Today at 06:52 AM 16
Period: 30.06.2026 Expectation: 3000 pips
Buying USDJPY up to 162.00
Yesterday at 11:39 AM 49
Go to forecasts